The news of U.S. FDA approval of our oncology drug, Nelarabine Injection, is a hugely significant milestone for us at Shorla Oncology. Nelarabine Injection is a critical treatment for patients living with T-cell Leukemia, particularly for children with leukemia, and it is our hope that today’s approval addresses the clinical need in this patient community.
Read more at:
https://www.businesswire.com/news/home/20230307005479/en/Shorla-Oncology-Announces-U.S.-FDA-Approval-of-Nelarabine-Injection-for-the-Treatment-of-T-cell-Leukemia
